Medpace (NASDAQ:MEDP) Releases FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 11.930-12.690 for the period, compared to the consensus estimate of 12.940. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Medpace Stock Down 7.5 %

Shares of MEDP stock opened at $327.86 on Wednesday. The company’s fifty day simple moving average is $344.13 and its two-hundred day simple moving average is $349.34. Medpace has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a market cap of $10.19 billion, a P/E ratio of 28.71, a PEG ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, analysts anticipate that Medpace will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on MEDP. William Blair reissued an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, TD Cowen decreased their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.